Gemcitabine-cisplatin Plus Avelumab or Gemcitabine-cisplatin as First-line Treatment of Patients With Locally Advanced or Metastatic Urothelial Bladder Carcinoma (GCISAVE)
Latest Information Update: 04 Mar 2024
At a glance
- Drugs Avelumab (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms GCISAVE
- 27 Jan 2024 Results (n=65) assessing efficacy and safety of combining avelumab with GCis in 1st line treatment, presented at the 2024 Genitourinary Cancers Symposium.
- 26 Apr 2022 Status changed from recruiting to discontinued.
- 30 Jul 2020 New trial record